Does Novavax Have a Viable Path Forward?

Novavax (NASDAQ: NVAX), a pre-revenue vaccine developer, is stuck between a rock and a hard place. Following the latest clinical failure of its respiratory syncytial virus (RSV) vaccine, ResVax, last month, the company could be forced into making some extremely tough choices soon.